Skip to main content
SpringerLink
Log in
Book cover

Pediatric and Adolescent Osteosarcoma pp 275–287Cite as

The Treatment of Nonmetastatic High Grade Osteosarcoma of the Extremity: Review of the Italian Rizzoli Experience. Impact on the Future

  • Chapter
  • First Online:

Part of the book series: Cancer Treatment and Research ((CTAR,volume 152))

Abstract

The Bone Tumor Center of the “Istituto Ortopedico Rizzoli” was established in 1955 with the aim of studying and treating the musculoskeletal tumors. Between 1959 and 2006, 1245 patients with high grade nonmetastatic osteosarcoma of the extremity were treated at our Institute. Most of them were enrolled in study protocols.

In the “prechemotherapy era”, the cure rate was 11%, with an amputation rate of 90%. Our first experience with adjuvant chemotherapy was in 1972. A total of 223 patients received adjuvant chemotherapy, with a disease-free survival (DFS) ranging from 45% to 53%, according to the chemotherapy protocol used. With the introduction of neoadjuvant chemotherapy, the resection rate increased and reached 94%, when high dose fosfamide was added to standard doses of methotrexate, cisplatin, and adriamycin.

In the last few years, the results of treatment of nonmetastatic osteosarcoma of the extremity have reached a plateau (64% five-year DFS), and strategies of dose intensification are not able to improve the prognosis. Not only new active drugs, but also different approaches to the disease, are needed.

In this regard, we are now investigating tumor microenvironment-targeted agents and chemotherapy protocols based on prospective biological stratification of patients.

Collaborative projects with international groups and institutions are crucial for this rare disease.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Campanacci M, Bacci G, Bertoni F, Picci P, Minutillo A, Franceschi C. The treatment of osteosarcoma of the extremities: twenty years experience at the Istituto Ortopedico Rizzoli. Cancer. 1981;48:533-542.

    Article  Google Scholar 

  2. Uribe-Botero G, Russel WO, Sutow WW, Martin RG. Primary osteosarcoma of bone: clinicopathological investigation of 243 cases, with necroscopy studies in 54. Am J Clin Pathol. 1977;67:427-435.

    CAS  PubMed  Google Scholar 

  3. Marcove RC, Mike V, Hajek JV, Levin AG, Hutter RV. Osteogenic sarcoma below the age of twenty-one. A review of one hundred and forty five cases. J Bone Joint Surg Am. 1970;52:411-423.

    CAS  PubMed  Google Scholar 

  4. Gaffney R, Unni KK, Sim FH, Slezak JM, Esther RJ, Bolander ME. Follow-up study of long-term survivors of osteosarcoma in the prechemotherapy era. Hum Pathol. 2006;37:1009-1014.

    Article  PubMed  Google Scholar 

  5. Cade S. Osteogenic sarcoma: a study based on 133 patients. J R Coll Surg Edinb. 1955;1:79-111.

    CAS  PubMed  Google Scholar 

  6. Jenkin RD, Allt WE, Fitzpatrick PJ. Osteosarcoma. An assessment of management with particular reference to primary irradiation and selective delayed amputation. Cancer. 1972;30:393-400.

    Article  CAS  PubMed  Google Scholar 

  7. Marcove RC, Miké V, Huvos AG, Southam CM, Levin AG. Vaccine trials for osteogenic sarcoma. A preliminary report. CA Cancer J Clin. 1973;23:74-80.

    Article  CAS  PubMed  Google Scholar 

  8. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer. 1972;30:1627-1631.

    Article  CAS  PubMed  Google Scholar 

  9. Cortes EP, Holland JF, Wang JJ, et al. Doxorubicin in disseminated osteosarcoma. JAMA. 1972;221:1132-1138.

    Article  Google Scholar 

  10. Bacci G, Gherlinzoni F, Picci P, et al. Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. Eur J Cancer Clin Oncol. 1986;22:1337-1345.

    Article  CAS  PubMed  Google Scholar 

  11. Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer. 1990;65:2539-2553.

    Article  CAS  PubMed  Google Scholar 

  12. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979;43:2163-2177.

    Article  CAS  PubMed  Google Scholar 

  13. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221-1230.

    Article  CAS  PubMed  Google Scholar 

  14. Ferrari S, Bacci G, Picci P, et al. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol. 1997;8:765-771.

    Article  CAS  PubMed  Google Scholar 

  15. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016-4027.

    CAS  PubMed  Google Scholar 

  16. Ferrari S, Mercuri M, Picci P, et al. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intra-arterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori. 1999;85:458-464.

    CAS  PubMed  Google Scholar 

  17. Winkler K, Bielack S, Delling G, et al. Effect of intra-arterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer. 1990;66:1703-1710.

    Article  CAS  PubMed  Google Scholar 

  18. Bacci G, Ferrari S, Longhi A, et al. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol. J Chemother. 2001;13:93-99.

    CAS  PubMed  Google Scholar 

  19. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Cancer. 2001;37:2030-2039.

    Article  CAS  PubMed  Google Scholar 

  20. Bacci G, Ferrari S, Longhi A, et al. Italian Sarcoma Group/Scandinavian Sarcoma Group. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother. 2002;14:198-206.

    CAS  PubMed  Google Scholar 

  21. Ferrari S, Smeland S, Mercuri M, et al. Italian and Scandinavian Sarcoma Groups. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845-8852.

    Article  PubMed  Google Scholar 

  22. ISG/OS-1 Protocol at: www.controlled-trials.com/ISRCTN21335128.

  23. Ferrari S, Bertoni F, Mercuri M, et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol. 2001;12:1145-1150.

    Article  CAS  PubMed  Google Scholar 

  24. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154-1161.

    Article  PubMed  Google Scholar 

  25. Baldini N, Scotlandi K, Barbanti-Bròdano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med. 1995;333:1380-1385.

    Article  CAS  PubMed  Google Scholar 

  26. Baldini N, Scotlandi K, Serra M, et al. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. J Orthop Res. 1999;17:629-632.

    Article  CAS  PubMed  Google Scholar 

  27. Serra M, Scotlandi K, Reverter-Branchat G, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol. 2003;21:536-542.

    Article  CAS  PubMed  Google Scholar 

  28. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999;17:2781-2788.

    CAS  PubMed  Google Scholar 

  29. Schwartz CL, Gorlick R, Teot L, et al. Children’s Oncology Group. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children’s Oncology Group. J Clin Oncol. 2007;25:2057-2062.

    Article  PubMed  Google Scholar 

  30. Serra M, Picci P, Ferrari S, Bacci G. Prognostic value of P-glycoprotein in high-grade osteosarcoma. Comment on: J Clin Oncol. 2007;25:2057-2062.

    Google Scholar 

  31. Ferrari S, Bertoni F, Zanella L, et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer. 2004;100:1936-1942.

    Article  CAS  PubMed  Google Scholar 

  32. Serra M, Pasello M, Manara MC, et al. Can P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Int J Oncol. 2006;29:1459-1468.

    CAS  PubMed  Google Scholar 

  33. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol. 2003;21:710-715.

    Article  PubMed  Google Scholar 

  34. Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol. 2002;20:2150-2156.

    Article  CAS  PubMed  Google Scholar 

  35. Bacci G, Forni C, Longhi A, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol. 2007;96:118-123.

    Article  PubMed  Google Scholar 

  36. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Cancer. 2001;37:2030–2039.

    Google Scholar 

  37. Ferrari S, Briccoli A, Mercuri M, et al. Late relapse in osteosarcoma. J Pediatr Hematol Oncol. 2006;28:418-422.

    Article  PubMed  Google Scholar 

  38. Longhi A, Ferrari S, Bacci G, Specchia S. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs. 2007;18:737-744.

    Article  CAS  PubMed  Google Scholar 

  39. Ferrari S, Pieretti F, Verri E, et al. Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate. Anticancer Drugs. 2005;16:733-738.

    Article  CAS  PubMed  Google Scholar 

  40. Longhi A, Porcu E, Petracchi S, Versari M, Conticini L, Bacci G. Reproductive functions in female patients treated with adjuvant and neoadjuvant chemotherapy for localized osteosarcoma of the extremity. Cancer. 2000;89:1961-1965.

    Article  CAS  PubMed  Google Scholar 

  41. Longhi A, Macchiagodena M, Vitali G, Bacci G. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol. 2003;25:292-296.

    Article  PubMed  Google Scholar 

  42. Bacci G, Ferrari C, Longhi A, et al. Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol. 2006;28:774-780.

    Article  PubMed  Google Scholar 

  43. Luciani F, Spada M, De Milito A, et al. Effect of proton pump inhibitor pre-treatment for resistance of solid tumor to cytotoxic drugs. J Natl Cancer Inst. 2004;96:1702-1713.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sezione di Chemioterapia, dei Tumori dell’ Apparato Locomotore, Istituto Ortopedico Rizzoli, via Pupilli 1, Bologna, 40136, Italy

    Stefano Ferrari

Authors
  1. Stefano Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emanuela Palmerini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eric L. Staals
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mario Mercuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bertoni Franco
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Piero Picci
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gaetano Bacci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefano Ferrari .

Editor information

Editors and Affiliations

  1. MD Anderson Cancer Center, University of Texas, Holcombe Blvd. 1515, Houston, 77030-4095, U.S.A.

    Norman Jaffe

  2. Dept. Medical Oncology, Norwegian Radium Hospital, Ullernschaussee 70, Oslo, 0310, Norway

    Oyvind S. Bruland

  3. Orthopädische Klinik, Olgahospital, Bismarckstraße 8, Stuttgart, 70176, Germany

    Stefan Bielack

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Ferrari, S. et al. (2009). The Treatment of Nonmetastatic High Grade Osteosarcoma of the Extremity: Review of the Italian Rizzoli Experience. Impact on the Future. In: Jaffe, N., Bruland, O., Bielack, S. (eds) Pediatric and Adolescent Osteosarcoma. Cancer Treatment and Research, vol 152. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-0284-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-0284-9_14

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-0283-2

  • Online ISBN: 978-1-4419-0284-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation